Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer

Basit Öğe Kaydı
dc.contributor.authorİyikesici, Mehmet Salih
dc.contributor.authorBaşaran, Gül
dc.contributor.authorDane, Faysal
dc.contributor.authorEkenel, Meltem
dc.contributor.authorYumuk, P. Fulden
dc.contributor.authorÇabuk, Devrim
dc.contributor.authorTurhal, N. Serdar
dc.date.accessioned2021-05-15T12:40:51Z
dc.date.available2021-05-15T12:40:51Z
dc.date.issued2014
dc.departmentTıp Fakültesi, Onkoloji Anabilim Dalıen_US
dc.descriptionYumuk, Perran Fulden/0000-0001-8650-299X;
dc.description.abstractThis study aimed to examine the associations between mitogen activated protein kinase (MAPK), Akt, and topoisomerase II expression and other well established clinical and pathological prognostic factors in patients with breast cancer. A total of 42 women with breast cancer who underwent anthracycline based chemotherapy were included in this retrospective study. Immunohistochemical methods were utilized to examine the expression of phosphorylated MAPK (pMAPK), phosphorylated Akt (pAkt), HER-2/neu and topoisomerase II alpha (topo II alpha) in tissue blocks. Subsequently, the associations between pMAPK, pAkt, and topoisomerase IIa (topo IIa) expression characteristics and disease stage (T and N), tumor grade, estrogen/progesteron receptor status, and HER-2/neu expression were explored. Median age of the patients was 63 years (range, 37-82). There was a significant association between N stage and topoisomerase IIa expression (P = 0.021), with increasing rates of positivity in higher grades: N0, 22.7%; N1, 11.1%; N2, 42.9%; N3, 100%. In addition, topo IIa expression was higher in estrogen receptor-positive versus estrogen receptor-negative tumors (50% vs. 0%, P = 0.0004) and MAPK expression was more frequent among progesteron receptor-positive versus negative tumors (64.0 versus 20.0%, P = 0.027). Our results show that the tissue expression of topo II alpha and MAPK, which play a role in the intracellular signal pathways, is associated with certain established prognostic factors in breast cancer. Further studies examining survival rates and involving larger sample populations are warranted to better define the importance of the observed associations.en_US
dc.identifier.endpage1464en_US
dc.identifier.issn1940-5901
dc.identifier.issue5en_US
dc.identifier.pmid24995112
dc.identifier.scopus2-s2.0-84902174350
dc.identifier.scopusqualityN/A
dc.identifier.startpage1459en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12939/696
dc.identifier.volume7en_US
dc.identifier.wosWOS:000341254800039
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorİyikesici, Mehmet Salih
dc.language.isoen
dc.publisherE-Century Publishing Corpen_US
dc.relation.ispartofInternational Journal of Clinical and Experimental Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast canceren_US
dc.subjectMitogen Activated Protein Kinase (MAPK)en_US
dc.subjectAkten_US
dc.subjectTopoisomerase IIen_US
dc.subjectHuman Epidermal Growth Factor Receptor-2/neu (HER-2/neu)en_US
dc.titleAssociations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu